Fundraising Fox
/Companies
Sign in

Renbioscience

1 employees on LinkedIn · 1 known investors

Find your way into Renbioscience

Each arrow is one introduction. Sign up to fill in the first one.

204 people can intro you to Ray

Ask Patrick Amiel to introduce you to Ray Stevens

You →Patrick · together at Andersen Consulting →Ray

Sign up to find every way you can get introduced to Renbioscience

  • Your email: who you already know at Renbioscience, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Renbioscience team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.

BiotechHealthtech

Founders & leadership

RSRay Stevens
Ray StevensChief Executive OfficerRay Stevens is Chief Executive Officer of Ren BioScience, which develops small-molecule therapies for inherited retinal diseases, acute kidney injury, and mitochondrial-driven conditions. He has held leadership roles at GSK and multiple venture-backed biotechnology companies, with experience spanning drug discovery through regulatory readiness and also advises biotech CEOs and boards on development strategy.
DBDale Bennyhoff
Dale BennyhoffChief Operating OfficerDale Bennyhoff is Chief Operating Officer at Ren BioScience. He brings expertise in CMC, quality, and regulatory strategy across drug development, with a track record of supporting IND clearances and regulatory submissions for early- and mid-stage biotech programs.
DSDr. Stewart McCallum
Dr. Stewart McCallumChief Medical Officer

Investors · 1

Related companies · 3

Dren BioDren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
RenBioRenBio develops DNA-based therapeutic technology that uses intramuscular injection of therapeutic-encoding "bioblueprints" so a patient's own muscle cells produce antibodies and therapeutic proteins to prevent and treat diseases, including infectious diseases. The company works in the antibody and therapeutic protein field, aiming to overcome obstacles in delivery, durability, and cost.
NeoGenomicsNeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.

Companies working in the same space as Renbioscience.

Frequently asked questions

What does Renbioscience do?
Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.
Who are Renbioscience's investors?
Renbioscience's investors include The Innovation Space.